Rituximab plus short-duration chemotherapy followed by Yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-hodgkin lymphoma: A phase II trial of the Sarah Cannon oncology research consortium

Clinical Lymphoma and Myeloma

Volumn 9, Issue 3, 2009, Pages 223-228

  Hainsworth, John ^a,b   Spigel, David ^a,b   Markus, Tiffanie ^a   Shipley, Dianna ^b   Thompson, Dana ^b   Rotman, Richard ^c   Dannaher, Charles ^d   Greco, F Anthony ^b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM   (United States)

^d Blood Disorders and Cancer ^*  (United States)

Author keywords

Consolidation therapy; Follicular lymphoma; Non Hodgkin's lymphoma; Radioimmunotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL; YTTRIUM;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLEEDING; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY REACTION; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; DISEASE FREE SURVIVAL; METHODOLOGY; MIDDLE AGED; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISOLONE; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; VINCRISTINE; YTTRIUM RADIOISOTOPES;

EID: 69149103542     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.044     Document Type: Article

References (18)

1. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417-23.
2. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26:4579-86.
3. Hiddemann W, Krebu M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone - results of a prospective randomized study of The German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725-32.
4. Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma: Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 2005; 106:106a (Abstract 349).
5. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology study. J Clin Oncol 2007; 25:1986-92.
6. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3262-9.
7. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26:5156-64.
8. Hainsworth JD, Litchy S, Morrissey LH, et al. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23:1500-6.
9. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:1244-55.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
11. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19:3918-28.
12. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109:1804-10.
13. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23:7565-73.
14. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352:441-9.
15. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I-131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005; 23:5696-704.
16. Zinzani PL, Tani M, Fanti S, et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 2008; 112:856-62.
17. Link B, Kaminski MS, Coleman M, et al. Phase II study of CVP followed by tositumomab and iodine I-131 tositumomab (Bexxar chemotherapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:562s (Abstract 6520).
18. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006; 24:4143-9.